PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “CONGRESSES”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 595 records · Page 33Linked to original sources
PubMed2005

The fix is in for Medicaid. With dollars 10 billion in Medicaid spending reductions approved by Congress, the next battle is over forming the commission.

It could have been worse. But then it could have been better. That was how healthcare providers assessed the Medicaid funding approved by Congress last week as part of the fiscal 2006 budget. Cuts in projected spending totaled dollars 10 billion over four years. "We fought against there being any cuts, but we think these are somewhat palatable," says the American Hospital Association's Tom Nickels, left.

Budgets↗
PubMed2001

International Xenotransplantation Association--sixth congress. Meeting the challenge of the new millennium.

The Sixth Congress of the International Xenotransplantion Association was a relatively small meeting, dealing with the most recent updates in this specialized field. The meeting covered all aspects of xenotransplantation, including physiological incompatibilities between donor animals and humans, genetic manipulation of pigs, immune biology of xenograft rejection, novel therapeutic agents, infectious risks, and ethics. It is clear that further gene manipulations within the potential pig donor are required before clinical trials involving the transplantation of most organs and tissues can commence. The overall impression was that of sustained progress in most areas, rather than any outstanding breakthroughs. On the other hand, there was no unexpected finding that would suggest that ultimately xenotransplantation is not feasible. New therapeutic agents with potential in future clinical trials were presented. In particular, the use of conjugates of galactose alpha-1,3 galactose (alpha-Gal), which are particularly effective in absorbing alpha-Gal antibodies, may be beneficial when pig organs progress to clinical trials.

Journal Article↗
PubMed2001

APL and differentiation therapy--joint international congress.

This meeting formed part of a series of bi-annual conferences, which had its beginnings in Sardinia in 1985, with the goal of promoting the concept of differentiation induction in cancer therapy. As in the past, the organizers of this meeting aimed to bring together both basic and clinical investigators to promote their interaction. Therapeutic successes of all trans-retinoic acid (ATRA), arsenic trioxide and STI-571 have proven the importance of oncogene-targeted therapies in cancer treatment, and underlie the usefulness of such interactions for effective and rational design of therapeutic approaches to combat malignant diseases. Consequently, discussions devoted to the clinical use of the above drugs, as well as to the molecular pathogeneses of the diseases in which these drugs are effective, occupied a considerable part of the congress. Although the clinical application of differentiation therapy still remains confined to acute promyelocytic leukemia (APL), some interesting data have began to emerge in other cancers where agents, such as arsenic trioxide, retinoids and ligands for other nuclear receptors, are showing some promise.

Journal Article↗
PubMed2005

European Atherosclerosis Society--75th congress.

The 75th European Atherosclerosis Society congress, held in Prague, Czech Republic, at the end of April 2005, was a large, well-attended meeting of international scientists with specialist interest in the field of cardiovascular diseases. Few new drugs emerged at the meeting as treatment options for cardiovascular diseases, however, many interesting basic and clinical data were presented that will eventually lead to better and improved cardiovascular therapies. This report is focused on recent advances in statin therapy (the TNT study and the role of pharmacogenetics in predicting individual response to statin therapy); clinical evidence of the combination therapy of ezetimibe + simvastatin; phase III clinical data on the selective cannabinoid type I receptor blocker rimonabant (sanofi-aventis); the role of peroxisome proliferator-activated receptor a agonists in the treatment of the metabolic syndrome; and the rationale for, and the recent advances in high-density lipoprotein-targeted therapy.

Anticholesteremic Agents↗
PubMed2001

Clinical microbiology and infectious diseases - 11th European Congress. 1-4 April 2001, Istanbul, Turkey.

This report covers the four different sessions of the congress. All sessions included the presentation of papers about treatment of respiratory tract infections (RTIs). RTIs account for 25% of all the community-acquired infections and are the second most frequent among nosocomial infections after urinary tract infections. Recent years have witnessed a great increase in resistance to antibiotics among pathogens causing RTIs. These changes have rendered several 'classical' antibiotics less effective in this indication. The drug industry has collectively made a great effort to develop new antibiotics to overcome this resistance. In the sessions described below, four different antibiotics were reviewed for their efficacy in RTIs. A relatively 'older' group comprising a beta-lactam and beta-lactamase-inhibitor combination was presented for use both in community and hospital settings. Two different quinolone antibiotics, levofloxacin (Daiichi Seiyaku) and moxifloxacin (Bayer), were the focus of another two sessions. In an era of penicillin resistance in Streptococcus pneumoniae and increasing importance of atypical organisms causing RTIs, the new fluoroquinolone derivatives have become critical agents. These new compounds are proving capable not only of eradicating troublesome pathogens, but also achieving this faster than any other drug. Finally, a new class of antibiotics, namely ketolides, was presented as a novel addition to the macrolide-lincosamide-streptogramin group. In vitro experiments and clinical experiments with telithromycin (Aventis Pharma), the first ketolide antimicrobial, were reported. All these presentations demonstrated telithromycin's potent activity against key respiratory pathogens, including resistant strains.

Journal Article↗
PubMed2005

A higher standard. Report tells Congress to let regulators strip tax-exempt status and go after boards that approve unreasonable executive pay.

It's time to give regulators the power to strip the tax-exempt status from charities that offer unreasonable executive compensation. That's the word from the Panel on the Nonprofit Sector's report to Congress. The report's 120 recommendations come amid increasing scrutiny of not-for-profits, and a spokesman for Sen. Chuck Grassley, left, says the Iowa lawmaker hopes to introduce legislation on the matter soon.

Chief Executive Officers, Hospital↗
PubMed2001

Drug therapy in HIV infection--Fifth International Congress.

At present, the optimal clinical management of HIV infection involves therapy with combinations of nucleoside and non-nucleoside reverse transcriptase inhibitors (NRTIs and NNRTIs, respectively) and protease inhibitors (PIs). Although these regimens are effective at reducing mortality and progression to AIDS, they fail to sustain a successful control of HIV RNA levels in a large proportion of patients; at the same time, resistance remains a major clinical problem. Development of novel antiretroviral drugs, with limited or no cross-resistance to existing drugs, that are more potent or that act by different mechanisms, is an obvious strategy to overcome such limitations. This report focuses on clinical trials of such selected drugs that were presented at this congress.

Journal Article↗
PubMed2005

Rare pulmonary diseases discussed at the Milan International Congress: facts and perspectives.

The Congress gathered together for two days most of the leading world authorities in the field of interstitial lung diseases: it was an outstanding basic and clinical update on most of the rare pulmonary diseases and orphan drugs in respiratory medicine. Here we examine the latest information outlined in the lectures and relative discussions, paying particular attention to anything of interest from a clinical point of view.

Humans↗
PubMed1999

Neuroscience--Fifth IBRO World Congress. 11-15 July 1999, Jerusalem, Israel.

This congress, held every four years by the International Brain Research Organization (IBRO) and the World Federation of Neuroscientists, included a broad range of neuroscience presentations including many of pharmacological relevance. Delegates presented data on the pharmacological characterization and mode of action of numerous drugs at this meeting.

Journal Article↗
PubMed1999

International Society of Heterocyclic Chemistry--17th international congress. 1-6 August 1999, Vienna, Austria.

Approximately 1200 scientists attended this congress of heterocyclic chemistry, which focused on: New synthetic methods in heterocyclic chemistry; synthesis of bioactive heterocycles including natural products; heterocycles and asymmetric synthesis; heterocycles in bioorganic chemistry; new heterocyclic materials; structure and properties of heterocyclic compounds; solid-phase synthesis, combinatorial chemistry and heterocyclic scaffolds. These topics were covered in 600 posters and 100 plenary, invited and oral presentations. This report summarizes the highlights of the presentations related to the category of the synthesis of bioactive heterocycles including natural products.

Journal Article↗
PubMed1999

EPHAR 99--Second European Congress of Pharmacology. 3-7 July 1999, Budapest, Hungary.

This meeting was chaired by Dr ES Vizi (Chairman of the Hungarian Pharmacological Society) and was attended by approximately 1600 delegates from 62 countries, including the USA, Canada, Israel, Japan and various parts of Europe. The opening ceremony was honored by the plenary lecture of a Nobel prize winner, Dr J Axelrod. The conference consisted of plenary sessions, 57 symposia and poster sessions. Each day the program included seven morning and seven afternoon symposia, simultaneously held, and a large poster section. The symposia focused on the neurotransmitter receptors as targets for the action of new drugs, new trends in the treatment of diabetes, Alzheimer's and Parkinson's diseases, psychiatric disorders, cardiac and gastrointestinal diseases and neuronal damage. All abstracts (more than 1200) were published in Fundamental and Clinical Pharmacology (1999) 13(Suppl 1). This year's meeting was substantially larger than the first EPHAR congress held in Milan, Italy, in 1995. It was generally well organized and served to introduce new basic and clinical knowledge in pharmacology.

Journal Article↗
PubMed2006

MS treatment optimization: report from the 21st ETRIMS/10th ACTRIMS Congress, 28 September-1 October 2005, Thessaloniki, Greece.

Around 3500 international delegates were presented with a broad scientific programme at the joint meeting of the 21st ECTRIMS and 10th ACTRIMS congress held last September. The meeting focused on the heterogeneity of MS and optimizing MS treatment--from the earliest stages to the long-term management of this chronic disease--with the goal of improving patient outcome.

Humans↗
PubMed2006

Inflammation, the key to much pathology. Highlights from the 7th World Congress on Inflammation, held August 20-24, 2005, in Melbourne, Australia.

From the World Congress on Inflammation, held August 20-24, 2005 in Melbourne, Australia, new targets and new drugs for inflammation of the respiratory system (asthma, allergic rhinitis, chronic obstructive pulmonary disease and cystic fibrosis), inflammatory bowel disease (ulcerative colitis and Crohn's disease), arthritis (rheumatoid and osteoarthritis), atherosclerosis and cancer are discussed.

Journal Article↗
PubMed1991

AIDS: debate on infection control guidelines shifts to Congress.

When Congress reconvenes this month, it will consider several bills aimed at protecting patients from AIDS. The American Hospital Association is supporting one requiring states to adopt the recommendations of the Centers for Disease Control by regulation or legislation. But the Senate has also passed a punitive amendment, which many AIDS experts and providers oppose.

Acquired Immunodeficiency Syndrome↗
PubMedDate not supplied

Reflections on the 101st congress.

Periodically, Washington, D.C. nursing leaders and nurse staffers on Capitol Hill have dinner meetings to exchange ideas and network. Nursing Economic+ hosted the most recent roundtable dinner on October 25, 1989, prior to its Sixth Annual Conference. In this speech, Sheila Burke, MPA, RN, FAAN, a founder of the Washington Roundtable dinner, reflects on the 101st Congress in action.

Delivery of Health Care↗
PubMed1990

Congress gears up for annual tug-of-war on health spending.

Health policymakers on Capitol Hill are gearing up for a tug-of-war with the Administration on the FY 1991 budget. But beyond budget battles, Washington analysts do not view this year as a significant one for major health care legislation. Still, there are a surprising number--and variety--of health care bills being introduced in Congress this session, some of which could significantly affect hospitals.

Financing, Government↗
PubMed1989

[Dermatology in Prague and the 1st Congress of the German Dermatology Society 1889].

Around 1900, dermatology as practised in Prague formed a link between Austria and Germany. The Congress of the German Dermatological Society held in 1889 in Prague was the first highlight of this connection. The topics and contents of the papers are characterized. The development of the dermatological clinics in Prague is described and their directors and research emphases are listed.

Czechoslovakia↗